EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Adverse Effects of Antidepressant Medications and their Management in Children and Adolescents

Jeffrey R Strawn iD, Jeffrey A Mills iD, Ethan A Poweleit, Laura B Ramsey iD, Paul E Croarkin iD

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2023-07 · 43 (7) · 675-690

DOI: 10.1002/phar.2767 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, online erschienen am 27.01.2023. Verfasst von Jeffrey R Strawn und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Behavioral Neuroscience, Anxiety Disorders Research Program, University of Cincinnati, Cincinnati, Ohio, USA. Hauptthemen laut MEDLINE: Selective Serotonin Reuptake Inhibitors, Serotonin and Noradrenaline Reuptake Inhibitors. Die Arbeit wurde bisher 186-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NICHD NIH HHS, Patient-Centered Outcomes Research Institute, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Selective serotonin reuptake inhibitors (SSRIs) and, to a lesser extent, serotonin‐norepinephrine reuptake inhibitors (SNRIs) are the cornerstone of pharmacotherapy for children and adolescents with anxiety and depressive disorders. These medications alleviate symptoms and restore function for many youths; however, they are associated with a distinct adverse effect profile, and their tolerability may complicate treatment or lead to discontinuation. Yet, SSRI/SNRI tolerability has received limited attention in the pediatric literature.

Methods

This review examines the early‐ (e.g., activation, gastrointestinal symptoms, sedation) and late‐emerging (e.g., weight gain) adverse effects of SSRIs and some SNRIs in pediatric patients.

Results

We provide a framework for discussing SSRI/SNRI tolerability with patients and their families and describe the pharmacologic basis, course, and predictors of adverse events in youth. Strategies to address specific tolerability concerns are presented. For selected adverse events, using posterior simulation of mean differences over time, we describe their course based on Physical Symptom Checklist measures in a prospective, randomized trial of anxious youth aged 7–17 years who were treated with sertraline ( n = 139) or placebo ( n = 76) for 12 weeks in the Child/Adolescent Anxiety Multimodal Study (CAMS). Main Results In CAMS, the relative severity/burden of total physical symptoms ( p < 0.001), insomnia ( p = 0.001), restlessness ( p < 0.001), nausea ( p = 0.002), abdominal pain ( p < 0.001), and dry mouth ( p = 0.024) decreased from baseline over 12 weeks of sertraline treatment, raising the possibility that these symptoms are transient. No significant changes were observed for sweating ( p = 0.103), constipation ( p = 0.241), or diarrhea ( p = 0.489). Finally, we review the antidepressant withdrawal syndrome in children and adolescents and provide guidance for SSRI discontinuation, using pediatric pharmacokinetic models of escitalopram and sertraline—two of the most used SSRIs in youth.

Conclusion

SSRI/SNRIs are associated with both early‐emerging (often transient) and late‐emerging adverse effects in youth. Pharmacokinetically‐informed appraoches may address some adverse effects and inform SSRI/SNRI discontinuation strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Selective Serotonin Reuptake InhibitorsSerotonin and Noradrenaline Reuptake InhibitorsAdolescentChildHumansSertralineProspective StudiesAntidepressive AgentsNorepinephrineSerotoninRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

CAMSactivationantidepressantselective serotonin reuptake inhibitor (SSRI, SRI)side effects

Substanzen

Selective Serotonin Reuptake InhibitorsSerotonin and Noradrenaline Reuptake InhibitorsSertralineAntidepressive AgentsNorepinephrineSerotonin

Autor:innen und Institutionen

  • Department of Psychiatry and Behavioral Neuroscience, Anxiety Disorders Research Program, University of Cincinnati, Cincinnati, Ohio, USA.
  • Division of Clinical Pharmacology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
  • Division of Child and Adolescent Psychiatry, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
  • Department of Economics, Lindner College of Business, University of Cincinnati, Cincinnati, Ohio, USA.
  • Division of Research in Patient Services, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
  • Division of Biomedical Informatics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

ORCID-Profile: Jeffrey R Strawn, Jeffrey A Mills, Laura B Ramsey, Paul E Croarkin

Förderung

  • NICHD NIH HHS
  • Patient-Centered Outcomes Research Institute
  • NCATS NIH HHS
  • NIMH NIH HHS
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development
  • National Center for Advancing Translational Sciences
  • National Institutes of Health
  • National Institute of Mental Health

Zitieren

APA

Strawn, J. R., Mills, J. A., Poweleit, E. A., Ramsey, L. B., & Croarkin, P. E. (2023). Adverse Effects of Antidepressant Medications and their Management in Children and Adolescents. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 43(7), 675-690. https://doi.org/10.1002/phar.2767

Vancouver

Strawn JR, Mills JA, Poweleit EA, Ramsey LB, Croarkin PE. Adverse Effects of Antidepressant Medications and their Management in Children and Adolescents. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2023;43(7):675-690. doi:10.1002/phar.2767

BibTeX
@article{Strawn2023,
  author = {Strawn, Jeffrey R and Mills, Jeffrey A and Poweleit, Ethan A and Ramsey, Laura B and Croarkin, Paul E},
  title = {Adverse Effects of Antidepressant Medications and their Management in Children and Adolescents},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2023},
  volume = {43},
  number = {7},
  pages = {675--690},
  doi = {10.1002/phar.2767}
}
Kostenlos starten →